Table Info

Table 2.

Inhibition or blockage of TSP4 expression through TSP4-AON or antibody reversed or prevented the development of behavioral hypersensitivity

Study	Animals (species/types)	Procedures	Results
Kim et al. [41], 2012	Male young adult Harlan Sprague-Dawley rats	TSP4 antibody 80 μg/rat, intrathecal, two weeks after L5/6 SNL	Both tactile allodynia and mechanic and thermal hyperalgesia reversed All effects peaked at 6 h after TSP4 antibody injection
		TSP4 antibody, 80 μg/rat per day, intrathecal immediately before, for eight days, and after SNL	Pre-emptive TSP4 antibody treatment prevented allodynia onset
		TSP4-AON, 50 μg/rat per day, intrathecal, for four days after SNL	Tactile allodynia and thermal and mechanical hyperalgesia reversed time-dependently
Zeng et al. [98], 2013	Adult female Sprague-Dawley rats	TSP4-AON, 50 μg/rat per day, intrathecal, post-SCI for four days	The antiallodynic effect developed after the last injection and lasted more than two days SCI-induced TSP4 expression was reduced in the DSC by 40%
Li et al. [97], 2014	Adult male Sprague-Dawley rats	TSP4-AON, 50 μg/10 μL per rat per day, intrathecal, for four consecutive days, starting at least three weeks post-CCI of the infraorbital nerve	After the last injection, the antiallodynic effect peaked at approximately one day and lasted over two days. Simultaneously, injury-induced TSP4 expression diminished in the C1/2 DSC
Crosby et al. [30], 2015	Adult male Holtzman rats	TSP4-AON, 75 μg/rat per day, intrathecal, for three days before FJD and seven days after FJD	Pre-emptive TSP4-AON treatment prevented the development of tactile allodynia and the increase in TSP4 expression in the C6/7 spinal cord following FJD FJD-induced excitatory synapse density is reduced in the superficial DH

Declarations

Acknowledgments

We want to thank Mr. Taylan Erekli for helping prepare the figures.

Author contributions

ND contributed to conceptualization, investigation, visualization, and project administration and wrote the original draft. AÖ and CC contributed the validation of the investigation, reviewed, and edited the article. All authors contributed to manuscript revision and read and approved the submitted version.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

Not applicable.

Copyright

References

McCarberg B, D’Arcy Y, Parsons B, Sadosky A, Thorpe A, Behar R. Neuropathic pain: a narrative review of etiology, assessment, diagnosis, and treatment for primary care providers. Curr Med Res Opin. 2017;33:1361–9. [DOI] [PubMed]

Zilliox LA. Neuropathic Pain. Continuum (Minneap Minn). 2017;23:512–32. [DOI] [PubMed]

Nicholson B, Verma S. Comorbidities in chronic neuropathic pain. Pain Med. 2004;5:S9–27. [DOI] [PubMed]

Sadosky A, McDermott AM, Brandenburg NA, Strauss M. A review of the epidemiology of painful diabetic peripheral neuropathy, postherpetic neuralgia, and less commonly studied neuropathic pain conditions. Pain Pract. 2008;8:45–56. [DOI] [PubMed]

Bouhassira D, Attal N. The multiple challenges of neuropathic pain. Neurosci Lett. 2019;702:6–10. [DOI] [PubMed]

Baron R, Binder A, Wasner G. Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment. Lancet Neurol. 2010;9:807–19. [DOI] [PubMed]

van Hecke O, Austin SK, Khan RA, Smith BH, Torrance N. Neuropathic pain in the general population: a systematic review of epidemiological studies. Pain. 2014;155:654–62. Erratum in: Pain. 2014;155:1907. [DOI] [PubMed]

Szewczyk AK, Jamroz-Wiśniewska A, Haratym N, Rejdak K. Neuropathic pain and chronic pain as an underestimated interdisciplinary problem. Int J Occup Med Environ Health. 2022;35:249–64. [DOI] [PubMed]

Cruccu G, Truini A. A review of neuropathic pain: from guidelines to clinical practice. Pain Ther. 2017;6:35–42. [DOI] [PubMed] [PMC]

10.

Cheraghali F, Tahamtan A, Hosseini SA, Gharib MH, Moradi A, Razavi Nikoo H, et al. Case report: detection of SARS-CoV-2 from cerebrospinal fluid in a 34-month-old child with encephalitis. Front Pediatr. 2021;9:565778. [DOI] [PubMed] [PMC]

11.

Luis MB, Liguori NF, López PA, Alonso R. SARS-CoV-2 RNA detection in cerebrospinal fluid: presentation of two cases and review of literature. Brain Behav Immun Health. 2021;15:100282. [DOI] [PubMed] [PMC]

12.

Novi G, Rossi T, Pedemonte E, Saitta L, Rolla C, Roccatagliata L, et al. Acute disseminated encephalomyelitis after SARS-CoV-2 infection. Neurol Neuroimmunol Neuroinflamm. 2020;7:e797. [DOI] [PubMed] [PMC]

13.

Zubair AS, McAlpine LS, Gardin T, Farhadian S, Kuruvilla DE, Spudich S. Neuropathogenesis and neurologic manifestations of the coronaviruses in the age of coronavirus disease 2019: a review. JAMA Neurol. 2020;77:1018–27. [DOI] [PubMed] [PMC]

14.

Attal N, Martinez V, Bouhassira D. Potential for increased prevalence of neuropathic pain after the COVID-19 pandemic. Pain Rep. 2021;6:e884. [DOI] [PubMed] [PMC]

15.

Schlereth T. Guideline “diagnosis and non interventional therapy of neuropathic pain” of the German Society of Neurology (deutsche Gesellschaft für Neurologie). Neurol Res Pract. 2020;2:16. [DOI] [PubMed] [PMC]

16.

Derry S, Bell RF, Straube S, Wiffen PJ, Aldington D, Moore RA. Pregabalin for neuropathic pain in adults. Cochrane Database Syst Rev. 2019;1:CD007076. [DOI] [PubMed] [PMC]

17.

NHS [Internet]. GGC chronic non malignant pain neuropathic pain guidelines. c2020 [cited 2022 Aug 9]. Available from: https://clinicalguidelines.nhsggc.org.uk/media/2568/chronic-nonmalignant-pain-202.pdf

18.

Neuropathic pain in adults: pharmacological management in non-specialist settings. NICE clinical guidelines, No. 173. London: National Institute for Health and Care Excellence (NICE); 2020.

19.

Cruccu G, Truini A; Neuropathic Pain Special Interest Group of the Italian Society of Neurology (Italian NeuPSIG). Neuropathic pain: the scope of the problem. Pain Ther. 2017;6:1–3. [DOI] [PubMed] [PMC]

20.

European Medicines Agency [Internet]. Guideline on the clinical development of medicinal products intended for the treatment of pain. c2016 [cited 2022 Aug 9]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-development-medicinal-products-intended-treatment-pain-first-version_en.pdf

21.

Moulin DE, Boulanger A, Clark AJ, Clarke H, Dao T, Finley GA, et al. Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society. Pain Res Manag. 2014;19:754693. [DOI] [PubMed] [PMC]

22.

van Velzen M, Dahan A, Niesters M. Neuropathic pain: challenges and opportunities. Front Pain Res (Lausanne). 2020;1:1. [DOI] [PubMed] [PMC]

23.

Meacham K, Shepherd A, Mohapatra DP, Haroutounian S. Neuropathic pain: central vs. peripheral mechanisms. Curr Pain Headache Rep. 2017;21:28. [DOI] [PubMed]

24.

Attal N, Bouhassira D. Pharmacotherapy of neuropathic pain: which drugs, which treatment algorithms? Pain. 2015;156:S104–14. [DOI] [PubMed]

25.

Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14:162–73. [DOI] [PubMed] [PMC]

26.

Butler S, Eek D, Ring L, Gordon A, Karlsten R. The utility/futility of medications for neuropathic pain - an observational study. Scand J Pain. 2019;19:327–35. [DOI] [PubMed]

27.

Freynhagen R, Baron R, Kawaguchi Y, Malik RA, Martire DL, Parsons B, et al. Pregabalin for neuropathic pain in primary care settings: recommendations for dosing and titration. Postgrad Med. 2021;133:1–9. [DOI] [PubMed]

28.

Jinesh S, Kullgren J, Shankar GS, Radhakrishnan R. Pharmaceutical perspective of neuropathic pain management for primary care providers. Inflammopharmacology. 2022;30:713–23. [DOI] [PubMed]

29.

Adams JC, Lawler J. The thrombospondins. Cold Spring Harb Perspect Biol. 2011;3:a009712. [DOI] [PubMed] [PMC]

30.

Crosby ND, Zaucke F, Kras JV, Dong L, Luo ZD, Winkelstein BA. Thrombospondin-4 and excitatory synaptogenesis promote spinal sensitization after painful mechanical joint injury. Exp Neurol. 2015;264:111–20. [DOI] [PubMed] [PMC]

31.

Risher WC, Eroglu C. Thrombospondins as key regulators of synaptogenesis in the central nervous system. Matrix Biol. 2012;31:170–7. [DOI] [PubMed] [PMC]

32.

Adams JC, Lawler J. The thrombospondins. Int J Biochem Cell Biol. 2004;36:961–8. [DOI] [PubMed] [PMC]

33.

Stenina OI, Desai SY, Krukovets I, Kight K, Janigro D, Topol EJ, et al. Thrombospondin-4 and its variants: expression and differential effects on endothelial cells. Circulation. 2003;108:1514–9. [DOI] [PubMed]

34.

Adams JC. Thrombospondins: multifunctional regulators of cell interactions. Annu Rev Cell Dev Biol. 2001;17:25–51. [DOI] [PubMed]

35.

Chen L, Chetkovich DM, Petralia RS, Sweeney NT, Kawasaki Y, Wenthold RJ, et al. Stargazin regulates synaptic targeting of AMPA receptors by two distinct mechanisms. Nature. 2000;408:936–43. [DOI] [PubMed]

36.

Arber S, Caroni P. Thrombospondin-4, an extracellular matrix protein expressed in the developing and adult nervous system promotes neurite outgrowth. J Cell Biol. 1995;131:1083–94. [DOI] [PubMed] [PMC]

37.

Bornstein P. Thrombospondins as matricellular modulators of cell function. J Clin Invest. 2001;107:929–34. [DOI] [PubMed] [PMC]

38.

Stenina-Adognravi O. Invoking the power of thrombospondins: regulation of thrombospondins expression. Matrix Biol. 2014;37:69–82. [DOI] [PubMed] [PMC]

39.

Adams JC. Functions of the conserved thrombospondin carboxy-terminal cassette in cell-extracellular matrix interactions and signaling. Int J Biochem Cell Biol. 2004;36:1102–14. [DOI] [PubMed]

40.

Baenziger NL, Brodie GN, Majerus PW. A thrombin-sensitive protein of human platelet membranes. Proc Natl Acad Sci U S A. 1971;68:240–3. [DOI] [PubMed] [PMC]

41.

Kim DS, Li KW, Boroujerdi A, Peter Yu Y, Zhou CY, Deng P, et al. Thrombospondin-4 contributes to spinal sensitization and neuropathic pain states. J Neurosci. 2012;32:8977–87. [DOI] [PubMed] [PMC]

42.

Wang B, Guo W, Huang Y. Thrombospondins and synaptogenesis. Neural Regen Res. 2012;7:1737–43. [DOI] [PubMed] [PMC]

43.

Carlson CB, Lawler J, Mosher DF. Thrombospondins: from structure to therapeutics. Cell Mol Life Sci. 2008;65:672. [DOI] [PubMed] [PMC]

44.

Yamagata K. Astrocyte-induced synapse formation and ischemic stroke. J Neurosci Res. 2021;99:1401–13. [DOI] [PubMed]

45.

Chung WS, Allen NJ, Eroglu C. Astrocytes control synapse formation, function, and elimination. Cold Spring Harb Perspect Biol. 2015;7:a020370. [DOI] [PubMed] [PMC]

46.

Hughes EG, Elmariah SB, Balice-Gordon RJ. Astrocyte secreted proteins selectively increase hippocampal GABAergic axon length, branching, and synaptogenesis. Mol Cell Neurosci. 2010;43:136–45. [DOI] [PubMed] [PMC]

47.

Ikeda H, Miyatake M, Koshikawa N, Ochiai K, Yamada K, Kiss A, et al. Morphine modulation of thrombospondin levels in astrocytes and its implications for neurite outgrowth and synapse formation. J Biol Chem. 2010;285:38415–27. [DOI] [PubMed] [PMC]

48.

Christopherson KS, Ullian EM, Stokes CCA, Mullowney CE, Hell JW, Agah A, et al. Thrombospondins are astrocyte-secreted proteins that promote CNS synaptogenesis. Cell. 2005;120:421–33. [DOI] [PubMed]

49.

Eroglu C, Allen NJ, Susman MW, O’Rourke NA, Park CY, Ozkan E, et al. Gabapentin receptor α2δ-1 is a neuronal thrombospondin receptor responsible for excitatory CNS synaptogenesis. Cell. 2009;139:380–92. [DOI] [PubMed] [PMC]

50.

Cáceres M, Suwyn C, Maddox M, Thomas JW, Preuss TM. Increased cortical expression of two synaptogenic thrombospondins in human brain evolution. Cereb Cortex. 2007;17:2312–21. [DOI] [PubMed]

51.

Osterhout DJ, Frazier WA, Higgins D. Thrombospondin promotes process outgrowth in neurons from the peripheral and central nervous systems. Dev Biol. 1992;150:256–65. [DOI] [PubMed]

52.

Lana B, Page KM, Kadurin I, Ho S, Nieto-Rostro M, Dolphin AC. Thrombospondin-4 reduces binding affinity of [³H]-gabapentin to calcium-channel α₂δ-1-subunit but does not interact with α₂δ-1 on the cell-surface when co-expressed. Sci Rep. 2016;6:24531. [DOI] [PubMed] [PMC]

53.

Baldwin KT, Eroglu C. Molecular mechanisms of astrocyte-induced synaptogenesis. Curr Opin Neurobiol. 2017;45:113–20. [DOI] [PubMed] [PMC]

54.

Cahoy JD, Emery B, Kaushal A, Foo LC, Zamanian JL, Christopherson KS, et al. A transcriptome database for astrocytes, neurons, and oligodendrocytes: a new resource for understanding brain development and function. J Neurosci. 2008;28:264–78. [DOI] [PubMed] [PMC]

55.

Cheng C, Lau SKM, Doering LC. Astrocyte-secreted thrombospondin-1 modulates synapse and spine defects in the fragile X mouse model. Mol Brain. 2016;9:74. [DOI] [PubMed] [PMC]

56.

Scott-Drew S, ffrench-Constant C. Expression and function of thrombospondin-1 in myelinating glial cells of the central nervous system. J Neurosci Res. 1997;50:202–14. [DOI] [PubMed]

57.

Stevens B. Neuron-astrocyte signaling in the development and plasticity of neural circuits. Neurosignals. 2008;16:278–88. [DOI] [PubMed]

58.

Eroglu C. The role of astrocyte-secreted matricellular proteins in central nervous system development and function. J Cell Commun Signal. 2009;3:167–76. [DOI] [PubMed] [PMC]

59.

Lawler J, Duquette M, Whittaker CA, Adams JC, McHenry K, DeSimone DW. Identification and characterization of thrombospondin-4, a new member of the thrombospondin gene family. J Cell Biol. 1993;120:1059–67. [DOI] [PubMed] [PMC]

60.

Frolova EG, Drazba J, Krukovets I, Kostenko V, Blech L, Harry C, et al. Control of organization and function of muscle and tendon by thrombospondin-4. Matrix Biol. 2014;37:35–48. [DOI] [PubMed] [PMC]

61.

Kim DS, Figueroa KW, Li KW, Boroujerdi A, Yolo T, Luo ZD. Profiling of dynamically changed gene expression in dorsal root ganglia post peripheral nerve injury and a critical role of injury-induced glial fibrillary acidic protein in maintenance of pain behaviors [corrected]. Pain. 2009;143:114–22. [DOI] [PubMed] [PMC]

62.

Menorca RMG, Fussell TS, Elfar JC. Nerve physiology: mechanisms of injury and recovery. Hand Clin. 2013;29:317–30. [DOI] [PubMed] [PMC]

63.

Smaila BD, Holland SD, Babaeijandaghi F, Henderson HG, Rossi FMV, Ramer MS. Systemic hypoxia mimicry enhances axonal regeneration and functional recovery following peripheral nerve injury. Exp Neurol. 2020;334:113436. [DOI] [PubMed]

64.

Bridges D, Thompson SWN, Rice ASC. Mechanisms of neuropathic pain. Br J Anaesth. 2001;87:12–26. [DOI] [PubMed]

65.

Wang Y, Wu J, Wu Z, Lin Q, Yue Y, Fang L. Regulation of AMPA receptors in spinal nociception. Mol Pain. 2010;6:5. [DOI] [PubMed] [PMC]

66.

Ro LS, Chang KH. Neuropathic pain: mechanisms and treatments. Chang Gung Med J. 2005;28:597–605. [PubMed]

67.

Schwartzman RJ, Grothusen J, Kiefer TR, Rohr P. Neuropathic central pain: epidemiology, etiology, and treatment options. Arch Neurol. 2001;58:1547–50. [DOI] [PubMed]

68.

Bahia PK, Suzuki R, Benton DCH, Jowett AJ, Chen MX, Trezise DJ, et al. A functional role for small-conductance calcium-activated potassium channels in sensory pathways including nociceptive processes. J Neurosci. 2005;25:3489–98. [DOI] [PubMed] [PMC]

69.

Perez-Reyes E. Molecular physiology of low-voltage-activated T-type calcium channels. Physiol Rev. 2003;83:117–61. [DOI] [PubMed]

70.

Murali SS, Napier IA, Mohammadi SA, Alewood PF, Lewis RJ, Christie MJ. High-voltage-activated calcium current subtypes in mouse DRG neurons adapt in a subpopulation-specific manner after nerve injury. J Neurophysiol. 2015;113:1511–9. [DOI] [PubMed]

71.

Pan B, Guo Y, Wu HE, Park J, Trinh VN, Luo ZD, et al. Thrombospondin-4 divergently regulates voltage-gated Ca²⁺ channel subtypes in sensory neurons after nerve injury. Pain. 2016;157:2068–80. [DOI] [PubMed] [PMC]

72.

Campbell JN, Meyer RA. Mechanisms of neuropathic pain. Neuron. 2006;52:77–92. [DOI] [PubMed] [PMC]

73.

Pan B, Yu H, Park J, Yu YP, Luo ZD, Hogan QH. Painful nerve injury upregulates thrombospondin-4 expression in dorsal root ganglia. J Neurosci Res. 2015;93:443–53. [DOI] [PubMed] [PMC]

74.

Lu SG, Zhang XL, Luo DZ, Gold MS. Persistent inflammation alters the density and distribution of voltage-activated calcium channels in subpopulations of rat cutaneous DRG neurons. Pain. 2010;151:633–43. [DOI] [PubMed] [PMC]

75.

Li CY, Zhang XL, Matthews EA, Li KW, Kurwa A, Boroujerdi A, et al. Calcium channel α₂δ₁ subunit mediates spinal hyperexcitability in pain modulation. Pain. 2006;125:20–34. [DOI] [PubMed] [PMC]

76.

Luo ZD, Chaplan SR, Higuera ES, Sorkin LS, Stauderman KA, Williams ME, et al. Upregulation of dorsal root ganglion α₂δ calcium channel subunit and its correlation with allodynia in spinal nerve-injured rats. J Neurosci. 2001;21:1868–75. [DOI] [PubMed] [PMC]

77.

Newton RA, Bingham S, Case PC, Sanger GJ, Lawson SN. Dorsal root ganglion neurons show increased expression of the calcium channel α2δ-1 subunit following partial sciatic nerve injury. Brain Res Mol Brain Res. 2001;95:1–8. [DOI] [PubMed]

78.

Bauer CS, Nieto-Rostro M, Rahman W, Tran-Van-Minh A, Ferron L, Douglas L, et al. The increased trafficking of the calcium channel subunit α₂δ-1 to presynaptic terminals in neuropathic pain is inhibited by the α₂δ ligand pregabalin. J Neurosci. 2009;29:4076–88. [DOI] [PubMed] [PMC]

79.

Li CY, Song YH, Higuera ES, Luo ZD. Spinal dorsal horn calcium channel α₂δ-1 subunit upregulation contributes to peripheral nerve injury-induced tactile allodynia. J Neurosci. 2004;24:8494–9. [DOI] [PubMed] [PMC]

80.

Chen J, Li L, Chen SR, Chen H, Xie JD, Sirrieh RE, et al. The α2δ-1-NMDA receptor complex is critically involved in neuropathic pain development and gabapentin therapeutic actions. Cell Rep. 2018;22:2307–21. [DOI] [PubMed] [PMC]

81.

Chincholkar M. Analgesic mechanisms of gabapentinoids and effects in experimental pain models: a narrative review. Br J Anaesth. 2018;120:1315–34. [DOI] [PubMed]

82.

Guo Y, Zhang Z, Wu HE, Luo ZD, Hogan QH, Pan B. Increased thrombospondin-4 after nerve injury mediates disruption of intracellular calcium signaling in primary sensory neurons. Neuropharmacology. 2017;117:292–304. [DOI] [PubMed] [PMC]

83.

Latremoliere A, Woolf CJ. Central sensitization: a generator of pain hypersensitivity by central neural plasticity. J Pain. 2009;10:895–926. [DOI] [PubMed] [PMC]

84.

Liu X, Chung K, Chung JM. Ectopic discharges and adrenergic sensitivity of sensory neurons after spinal nerve injury. Brain Res. 1999;849:244–7. [DOI] [PubMed]

85.

Harte SE, Harris RE, Clauw DJ. The neurobiology of central sensitization. J Appl Behav Res. 2018;23:e12137. [DOI]

86.

Jensen TS, Finnerup NB. Neuropathic pain: peripheral and central mechanisms. Eur J Pain Suppl. 2009;3:33–6. [DOI]

87.

Loeser JD, Treede RD. The Kyoto protocol of IASP basic pain terminology. Pain. 2008;137:473–7. [DOI] [PubMed]

88.

Hains BC, Saab CY, Klein JP, Craner MJ, Waxman SG. Altered sodium channel expression in second-order spinal sensory neurons contributes to pain after peripheral nerve injury. J Neurosci. 2004;24:4832–9. [DOI] [PubMed] [PMC]

89.

Milligan ED, Watkins LR. Pathological and protective roles of glia in chronic pain. Nat Rev Neurosci. 2009;10:23–36. [DOI] [PubMed] [PMC]

90.

Chiang CY, Sessle BJ, Dostrovsky JO. Role of astrocytes in pain. Neurochem Res. 2012;37:2419–31. [DOI] [PubMed]

91.

Jones EV, Bouvier DS. Astrocyte-secreted matricellular proteins in CNS remodelling during development and disease. Neural Plast. 2014;2014:321209. [DOI] [PubMed] [PMC]

92.

Obata H, Sakurazawa S, Kimura M, Saito S. Activation of astrocytes in the spinal cord contributes to the development of bilateral allodynia after peripheral nerve injury in rats. Brain Res. 2010;1363:72–80. [DOI] [PubMed]

93.

Park J, Yu YP, Zhou CY, Li KW, Wang D, Chang E, et al. Central mechanisms mediating thrombospondin-4-induced pain states. J Biol Chem. 2016;291:13335–48. [DOI] [PubMed] [PMC]

94.

Ji RR, Berta T, Nedergaard M. Glia and pain: is chronic pain a gliopathy? Pain. 2013;154:S10–28. [DOI] [PubMed] [PMC]

95.

Düzenli N, Ülker S, Şengül G, Kayhan B, Önal A. Effects of cyanocobalamin and its combination with morphine on neuropathic rats and the relationship between these effects and thrombospondin-4 expression. Korean J Pain. 2022;35:66–77. [DOI] [PubMed] [PMC]

96.

Crosby ND, Winkelstein BA. Spinal astrocytic thrombospondin-4 induced by excitatory neuronal signaling mediates pain after facet capsule injury. Ann Biomed Eng. 2016;44:3215–24. [DOI] [PubMed] [PMC]

97.

Li KW, Kim DS, Zaucke F, Luo ZD. Trigeminal nerve injury-induced thrombospondin-4 up-regulation contributes to orofacial neuropathic pain states in a rat model. Eur J Pain. 2014;18:489–95. [DOI] [PubMed] [PMC]

98.

Zeng J, Kim D, Li KW, Sharp K, Steward O, Zaucke F, et al. Thrombospondin-4 contributes to spinal cord injury-induced changes in nociception. Eur J Pain. 2013;17:1458–64. [DOI] [PubMed] [PMC]

99.

Park JF, Yu YP, Gong N, Trinh VN, Luo ZD. The EGF-LIKE domain of thrombospondin-4 is a key determinant in the development of pain states due to increased excitatory synaptogenesis. J Biol Chem. 2018;293:16453–63. [DOI] [PubMed] [PMC]

100.

Yu YP, Gong N, Kweon TD, Vo B, Luo ZD. Gabapentin prevents synaptogenesis between sensory and spinal cord neurons induced by thrombospondin-4 acting on pre-synaptic Ca_vα₂δ₁ subunits and involving T-type Ca²⁺ channels. Br J Pharmacol. 2018;175:2348–61. [DOI] [PubMed] [PMC]

101.

El-Awaad E, Pryymachuk G, Fried C, Matthes J, Isensee J, Hucho T, et al. Direct, gabapentin-insensitive interaction of a soluble form of the calcium channel subunit α₂δ-1 with thrombospondin-4. Sci Rep. 2019;9:16272. [DOI] [PubMed] [PMC]